Los Angeles Capital Management LLC Makes New $379,000 Investment in Immunome, Inc. (NASDAQ:IMNM)

Los Angeles Capital Management LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 35,721 shares of the company's stock, valued at approximately $379,000. Los Angeles Capital Management LLC owned 0.06% of Immunome as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its position in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after acquiring an additional 237,497 shares during the period. Geode Capital Management LLC raised its stake in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after acquiring an additional 144,557 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after purchasing an additional 85,580 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Immunome Stock Up 2.1 %

IMNM traded up $0.19 on Friday, reaching $9.41. The company had a trading volume of 240,340 shares, compared to its average volume of 917,847. Immunome, Inc. has a 1 year low of $8.55 and a 1 year high of $28.19. The stock has a market capitalization of $750.94 million, a PE ratio of -1.16 and a beta of 1.93. The stock has a 50-day moving average price of $10.18 and a 200-day moving average price of $12.06.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IMNM. Piper Sandler decreased their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective on the stock. Finally, Wedbush reiterated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $28.60.

Insider Activity

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.60% of the company's stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.